216 related articles for article (PubMed ID: 9007720)
1. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis.
Forrest EH; Bouchier IA; Hayes PC
J Hepatol; 1996 Dec; 25(6):909-15. PubMed ID: 9007720
[TBL] [Abstract][Full Text] [Related]
2. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension.
Tripathi D; Therapondos G; Lui HF; Stanley AJ; Hayes PC
Aliment Pharmacol Ther; 2002 Mar; 16(3):373-80. PubMed ID: 11876689
[TBL] [Abstract][Full Text] [Related]
3. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis.
Stanley AJ; Therapondos G; Helmy A; Hayes PC
J Hepatol; 1999 Mar; 30(3):479-84. PubMed ID: 10190732
[TBL] [Abstract][Full Text] [Related]
4. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Hobolth L; Bendtsen F; Hansen EF; Møller S
Dig Liver Dis; 2014 Mar; 46(3):251-6. PubMed ID: 24290869
[TBL] [Abstract][Full Text] [Related]
5. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
[TBL] [Abstract][Full Text] [Related]
6. Carvedilol or propranolol in portal hypertension? A randomized comparison.
Hobolth L; Møller S; Grønbæk H; Roelsgaard K; Bendtsen F; Feldager Hansen E
Scand J Gastroenterol; 2012 Apr; 47(4):467-74. PubMed ID: 22401315
[TBL] [Abstract][Full Text] [Related]
7. The effects of carvedilol a nonselective beta-blocker on portal hemodynamics in cirrhosis.
Fierbinteanu-Braticevici C; Udeanu M; Dragomir P; Andronescu D
Rom J Intern Med; 2003; 41(3):247-54. PubMed ID: 15526508
[TBL] [Abstract][Full Text] [Related]
8. Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker with nitrovasodilating properties, in patients with portal hypertension due to cirrhosis. A comparative study with propranolol.
Aramaki T; Sekiyama T; Katsuta Y; Kurokawa H; Komeichi H; Tsutsui H; Terada H; Ohsuga M; Satomura K; Okumura H
J Hepatol; 1992 May; 15(1-2):48-53. PubMed ID: 1354676
[TBL] [Abstract][Full Text] [Related]
9. Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
De BK; Das D; Sen S; Biswas PK; Mandal SK; Majumdar D; Maity AK
J Gastroenterol Hepatol; 2002 Feb; 17(2):183-9. PubMed ID: 11966949
[TBL] [Abstract][Full Text] [Related]
10. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
[TBL] [Abstract][Full Text] [Related]
11. Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension.
Sekiyama T; Komeichi H; Nagano T; Ohsuga M; Terada H; Katsuta Y; Satomura K; Aramaki T
Arzneimittelforschung; 1997 Apr; 47(4):353-5. PubMed ID: 9150854
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Sinagra E; Perricone G; D'Amico M; Tinè F; D'Amico G
Aliment Pharmacol Ther; 2014 Mar; 39(6):557-68. PubMed ID: 24461301
[TBL] [Abstract][Full Text] [Related]
13. Effect of carvedilol on portal pressure estimated by hepatic vein Doppler ultrasound waveform and damping index in cirrhotic patients.
Hussain Q; Badruddin AH; Chaudhry MA; Ahmad F; Abbasi A
J Coll Physicians Surg Pak; 2010 Sep; 20(9):586-9. PubMed ID: 20810049
[TBL] [Abstract][Full Text] [Related]
14. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of nipradilol and the acute and chronic splanchnic hemodynamic effects of a new beta-blocker with nitrovasodilating properties in patients with liver cirrhosis.
Sugano S; Kawafune T; Suzuki T; Kubota M; Okajima T; Sumino Y; Akita H
Am J Gastroenterol; 1995 May; 90(5):788-93. PubMed ID: 7733089
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
Reiberger T; Ulbrich G; Ferlitsch A; Payer BA; Schwabl P; Pinter M; Heinisch BB; Trauner M; Kramer L; Peck-Radosavljevic M;
Gut; 2013 Nov; 62(11):1634-41. PubMed ID: 23250049
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
18. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Abshagen U
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
[TBL] [Abstract][Full Text] [Related]
19. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Reiberger T; Ferlitsch A; Payer BA; Pinter M; Homoncik M; Peck-Radosavljevic M;
J Gastroenterol; 2012 May; 47(5):561-8. PubMed ID: 22170417
[TBL] [Abstract][Full Text] [Related]
20. After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis?
Wani ZA; Baht RA; Bhadoria AS; Maiwall R; Majeed Y; Khan AA; Zargar SA; Shah MA; Khan KM
Saudi J Gastroenterol; 2015; 21(5):278-83. PubMed ID: 26458853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
